nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ERBB2—duct of salivary gland—salivary gland cancer	0.213	0.627	CbGeAlD
Afatinib—ERBB2—neck—salivary gland cancer	0.0121	0.0356	CbGeAlD
Afatinib—ERBB2—saliva-secreting gland—salivary gland cancer	0.00946	0.0278	CbGeAlD
Afatinib—ERBB4—saliva-secreting gland—salivary gland cancer	0.00946	0.0278	CbGeAlD
Afatinib—BLK—lymphoid tissue—salivary gland cancer	0.00927	0.0273	CbGeAlD
Afatinib—ERBB2—connective tissue—salivary gland cancer	0.00869	0.0255	CbGeAlD
Afatinib—ERBB4—epithelium—salivary gland cancer	0.00825	0.0242	CbGeAlD
Afatinib—ERBB2—epithelium—salivary gland cancer	0.00825	0.0242	CbGeAlD
Afatinib—ERBB2—lymphoid tissue—salivary gland cancer	0.00635	0.0187	CbGeAlD
Afatinib—DYRK1A—lymphoid tissue—salivary gland cancer	0.00612	0.018	CbGeAlD
Afatinib—BLK—lymph node—salivary gland cancer	0.00523	0.0154	CbGeAlD
Afatinib—ABL1—parotid gland—salivary gland cancer	0.00414	0.0122	CbGeAlD
Afatinib—PHKG2—lymph node—salivary gland cancer	0.00399	0.0117	CbGeAlD
Afatinib—ABL1—saliva-secreting gland—salivary gland cancer	0.00396	0.0116	CbGeAlD
Afatinib—ABL1—connective tissue—salivary gland cancer	0.00364	0.0107	CbGeAlD
Afatinib—ERBB2—lymph node—salivary gland cancer	0.00358	0.0105	CbGeAlD
Afatinib—DYRK1A—lymph node—salivary gland cancer	0.00345	0.0101	CbGeAlD
Afatinib—EGFR—lymph node—salivary gland cancer	0.00304	0.00893	CbGeAlD
Afatinib—IRAK1—lymph node—salivary gland cancer	0.00268	0.00788	CbGeAlD
Afatinib—ABL1—lymphoid tissue—salivary gland cancer	0.00266	0.00783	CbGeAlD
Afatinib—LCK—lymph node—salivary gland cancer	0.00262	0.00769	CbGeAlD
Afatinib—ABCG2—parotid gland—salivary gland cancer	0.00261	0.00767	CbGeAlD
Afatinib—ABCG2—saliva-secreting gland—salivary gland cancer	0.0025	0.00735	CbGeAlD
Afatinib—ABL1—lymph node—salivary gland cancer	0.0015	0.00442	CbGeAlD
Afatinib—ABCB1—epithelium—salivary gland cancer	0.00107	0.00316	CbGeAlD
Afatinib—ABCG2—lymph node—salivary gland cancer	0.000947	0.00278	CbGeAlD
Afatinib—ABCB1—lymphoid tissue—salivary gland cancer	0.000828	0.00243	CbGeAlD
Afatinib—ABCB1—lymph node—salivary gland cancer	0.000467	0.00137	CbGeAlD
Afatinib—EGFR—Signaling by PDGF—HRAS—salivary gland cancer	7.54e-05	0.000114	CbGpPWpGaD
Afatinib—IRAK1—Immune System—MAP2K2—salivary gland cancer	7.53e-05	0.000114	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—CREBBP—salivary gland cancer	7.52e-05	0.000114	CbGpPWpGaD
Afatinib—EGFR—Immune System—FGFR4—salivary gland cancer	7.43e-05	0.000113	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—PIK3CA—salivary gland cancer	7.43e-05	0.000113	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—HRAS—salivary gland cancer	7.43e-05	0.000113	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—HRAS—salivary gland cancer	7.43e-05	0.000113	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—HRAS—salivary gland cancer	7.43e-05	0.000113	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—PIK3CA—salivary gland cancer	7.38e-05	0.000112	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—HRAS—salivary gland cancer	7.36e-05	0.000112	CbGpPWpGaD
Afatinib—BLK—Immune System—CREBBP—salivary gland cancer	7.33e-05	0.000111	CbGpPWpGaD
Afatinib—EGFR—Immune System—FBXW7—salivary gland cancer	7.31e-05	0.000111	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—HRAS—salivary gland cancer	7.29e-05	0.000111	CbGpPWpGaD
Afatinib—EGFR—Focal Adhesion—HRAS—salivary gland cancer	7.28e-05	0.00011	CbGpPWpGaD
Afatinib—BLK—Immune System—CDH1—salivary gland cancer	7.28e-05	0.00011	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—CREBBP—salivary gland cancer	7.27e-05	0.00011	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—HRAS—salivary gland cancer	7.26e-05	0.00011	CbGpPWpGaD
Afatinib—PHKG2—Disease—PIK3CA—salivary gland cancer	7.26e-05	0.00011	CbGpPWpGaD
Afatinib—ABL1—Immune System—FOXO3—salivary gland cancer	7.22e-05	0.000109	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—JAG1—salivary gland cancer	7.22e-05	0.000109	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FGFR4—salivary gland cancer	7.19e-05	0.000109	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MARCKS—salivary gland cancer	7.17e-05	0.000109	CbGpPWpGaD
Afatinib—LCK—Immune System—FGFR4—salivary gland cancer	7.16e-05	0.000109	CbGpPWpGaD
Afatinib—ERBB2—Disease—CREBBP—salivary gland cancer	7.14e-05	0.000108	CbGpPWpGaD
Afatinib—EGFR—B Cell Activation—HRAS—salivary gland cancer	7.13e-05	0.000108	CbGpPWpGaD
Afatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—salivary gland cancer	7.13e-05	0.000108	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—PIK3CA—salivary gland cancer	7.11e-05	0.000108	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FBXW7—salivary gland cancer	7.07e-05	0.000107	CbGpPWpGaD
Afatinib—LCK—Immune System—FBXW7—salivary gland cancer	7.05e-05	0.000107	CbGpPWpGaD
Afatinib—ERBB4—Disease—CREBBP—salivary gland cancer	7.04e-05	0.000107	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—HRAS—salivary gland cancer	7.01e-05	0.000106	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—NUP62—salivary gland cancer	6.96e-05	0.000106	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—VCAN—salivary gland cancer	6.91e-05	0.000105	CbGpPWpGaD
Afatinib—EGFR—Disease—JAG1—salivary gland cancer	6.89e-05	0.000104	CbGpPWpGaD
Afatinib—LCK—Hemostasis—CREBBP—salivary gland cancer	6.88e-05	0.000104	CbGpPWpGaD
Afatinib—LCK—B Cell Activation—HRAS—salivary gland cancer	6.87e-05	0.000104	CbGpPWpGaD
Afatinib—EGFR—Disease—FGFR4—salivary gland cancer	6.86e-05	0.000104	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—PTEN—salivary gland cancer	6.86e-05	0.000104	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—HRAS—salivary gland cancer	6.82e-05	0.000103	CbGpPWpGaD
Afatinib—EGFR—Disease—FBXW7—salivary gland cancer	6.75e-05	0.000102	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MAP2K2—salivary gland cancer	6.74e-05	0.000102	CbGpPWpGaD
Afatinib—LCK—Platelet activation, signaling and aggregation—PIK3CA—salivary gland cancer	6.72e-05	0.000102	CbGpPWpGaD
Afatinib—PHKG2—Disease—HRAS—salivary gland cancer	6.72e-05	0.000102	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—PIK3CA—salivary gland cancer	6.69e-05	0.000101	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PYGB—salivary gland cancer	6.66e-05	0.000101	CbGpPWpGaD
Afatinib—LCK—Disease—JAG1—salivary gland cancer	6.64e-05	0.000101	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MAP2K2—salivary gland cancer	6.63e-05	0.000101	CbGpPWpGaD
Afatinib—LCK—Disease—FGFR4—salivary gland cancer	6.61e-05	0.0001	CbGpPWpGaD
Afatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—salivary gland cancer	6.6e-05	0.0001	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—PIK3CA—salivary gland cancer	6.59e-05	9.99e-05	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—HRAS—salivary gland cancer	6.58e-05	9.97e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—EP300—salivary gland cancer	6.54e-05	9.92e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGF16—salivary gland cancer	6.51e-05	9.86e-05	CbGpPWpGaD
Afatinib—LCK—Disease—FBXW7—salivary gland cancer	6.51e-05	9.86e-05	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—PIK3CA—salivary gland cancer	6.43e-05	9.74e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—CREBBP—salivary gland cancer	6.42e-05	9.73e-05	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—PIK3CA—salivary gland cancer	6.33e-05	9.6e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGF16—salivary gland cancer	6.27e-05	9.5e-05	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—HRAS—salivary gland cancer	6.19e-05	9.39e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—CREBBP—salivary gland cancer	6.19e-05	9.38e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—FOXO3—salivary gland cancer	6.17e-05	9.35e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—CDH1—salivary gland cancer	6.12e-05	9.28e-05	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—HRAS—salivary gland cancer	6.1e-05	9.25e-05	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—PIK3CA—salivary gland cancer	6.09e-05	9.23e-05	CbGpPWpGaD
Afatinib—PHKG2—Metabolism—PIK3CA—salivary gland cancer	6.08e-05	9.22e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FOXO3—salivary gland cancer	5.96e-05	9.04e-05	CbGpPWpGaD
Afatinib—ERBB2—Adaptive Immune System—HRAS—salivary gland cancer	5.95e-05	9.01e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—FOXO3—salivary gland cancer	5.94e-05	9.01e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—CDH1—salivary gland cancer	5.9e-05	8.94e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAP2K2—salivary gland cancer	5.89e-05	8.93e-05	CbGpPWpGaD
Afatinib—ERBB4—Adaptive Immune System—HRAS—salivary gland cancer	5.86e-05	8.88e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—salivary gland cancer	5.81e-05	8.8e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—EP300—salivary gland cancer	5.8e-05	8.79e-05	CbGpPWpGaD
Afatinib—ABCG2—Transmembrane transport of small molecules—CREBBP—salivary gland cancer	5.77e-05	8.74e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—FOXO3—salivary gland cancer	5.69e-05	8.63e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—EP300—salivary gland cancer	5.69e-05	8.62e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—PIK3CA—salivary gland cancer	5.67e-05	8.6e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAML2—salivary gland cancer	5.65e-05	8.56e-05	CbGpPWpGaD
Afatinib—BLK—Adaptive Immune System—HRAS—salivary gland cancer	5.64e-05	8.54e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—salivary gland cancer	5.61e-05	8.5e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CREBBP—salivary gland cancer	5.59e-05	8.48e-05	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—PIK3CA—salivary gland cancer	5.56e-05	8.43e-05	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—HRAS—salivary gland cancer	5.56e-05	8.43e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—CDH1—salivary gland cancer	5.55e-05	8.42e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—PTEN—salivary gland cancer	5.53e-05	8.38e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NOTCH1—salivary gland cancer	5.52e-05	8.36e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—MAP2K2—salivary gland cancer	5.51e-05	8.35e-05	CbGpPWpGaD
Afatinib—LCK—Disease—FOXO3—salivary gland cancer	5.49e-05	8.32e-05	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—PIK3CA—salivary gland cancer	5.47e-05	8.29e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAML2—salivary gland cancer	5.45e-05	8.25e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—PTEN—salivary gland cancer	5.44e-05	8.25e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NOTCH1—salivary gland cancer	5.44e-05	8.24e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PHGDH—salivary gland cancer	5.43e-05	8.23e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—PTEN—salivary gland cancer	5.37e-05	8.14e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—salivary gland cancer	5.35e-05	8.1e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—EP300—salivary gland cancer	5.27e-05	7.99e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—HRAS—salivary gland cancer	5.25e-05	7.96e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—PTEN—salivary gland cancer	5.24e-05	7.94e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ST3GAL4—salivary gland cancer	5.23e-05	7.92e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—EP300—salivary gland cancer	5.19e-05	7.87e-05	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—HRAS—salivary gland cancer	5.15e-05	7.8e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—EP300—salivary gland cancer	5.12e-05	7.76e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—PTEN—salivary gland cancer	5.1e-05	7.73e-05	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—HRAS—salivary gland cancer	5.06e-05	7.67e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAP2K2—salivary gland cancer	5.04e-05	7.63e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—PTEN—salivary gland cancer	5.03e-05	7.62e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CREBBP—salivary gland cancer	5e-05	7.58e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—EP300—salivary gland cancer	4.99e-05	7.57e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—EP300—salivary gland cancer	4.95e-05	7.51e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CREBBP—salivary gland cancer	4.93e-05	7.47e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAP2K2—salivary gland cancer	4.87e-05	7.38e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—EP300—salivary gland cancer	4.87e-05	7.37e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MAP2K2—salivary gland cancer	4.85e-05	7.36e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—PIK3CA—salivary gland cancer	4.84e-05	7.33e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—JAG1—salivary gland cancer	4.83e-05	7.31e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGFR4—salivary gland cancer	4.81e-05	7.28e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—EP300—salivary gland cancer	4.79e-05	7.26e-05	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—HRAS—salivary gland cancer	4.75e-05	7.2e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AQP1—salivary gland cancer	4.75e-05	7.2e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FBXW7—salivary gland cancer	4.73e-05	7.16e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—EP300—salivary gland cancer	4.68e-05	7.1e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—JAG1—salivary gland cancer	4.65e-05	7.05e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MAP2K2—salivary gland cancer	4.65e-05	7.05e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGFR4—salivary gland cancer	4.63e-05	7.02e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—PTEN—salivary gland cancer	4.59e-05	6.95e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FBXW7—salivary gland cancer	4.56e-05	6.9e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MAP2K2—salivary gland cancer	4.48e-05	6.79e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—HRAS—salivary gland cancer	4.48e-05	6.79e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—PTEN—salivary gland cancer	4.42e-05	6.7e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—PTEN—salivary gland cancer	4.4e-05	6.68e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CREBBP—salivary gland cancer	4.38e-05	6.64e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—EP300—salivary gland cancer	4.37e-05	6.63e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—CDH1—salivary gland cancer	4.35e-05	6.59e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—PTEN—salivary gland cancer	4.24e-05	6.43e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—EP300—salivary gland cancer	4.22e-05	6.39e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—PIK3CA—salivary gland cancer	4.21e-05	6.38e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—TP53—salivary gland cancer	4.07e-05	6.17e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PTEN—salivary gland cancer	4e-05	6.06e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NOTCH1—salivary gland cancer	3.99e-05	6.05e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FOXO3—salivary gland cancer	3.99e-05	6.04e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—HRAS—salivary gland cancer	3.97e-05	6.01e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—salivary gland cancer	3.96e-05	5.99e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—PIK3CA—salivary gland cancer	3.9e-05	5.91e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—HRAS—salivary gland cancer	3.89e-05	5.9e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FOXO3—salivary gland cancer	3.84e-05	5.82e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—PIK3CA—salivary gland cancer	3.84e-05	5.82e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—salivary gland cancer	3.83e-05	5.8e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EP300—salivary gland cancer	3.81e-05	5.77e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NOTCH1—salivary gland cancer	3.81e-05	5.77e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—PIK3CA—salivary gland cancer	3.79e-05	5.74e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NUP62—salivary gland cancer	3.77e-05	5.71e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CREBBP—salivary gland cancer	3.74e-05	5.67e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—VCAN—salivary gland cancer	3.74e-05	5.66e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDH1—salivary gland cancer	3.71e-05	5.63e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CCND1—salivary gland cancer	3.7e-05	5.61e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—PIK3CA—salivary gland cancer	3.69e-05	5.6e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NOTCH1—salivary gland cancer	3.67e-05	5.56e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CCND1—salivary gland cancer	3.65e-05	5.53e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CREBBP—salivary gland cancer	3.62e-05	5.48e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—HRAS—salivary gland cancer	3.61e-05	5.47e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CREBBP—salivary gland cancer	3.61e-05	5.46e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—PIK3CA—salivary gland cancer	3.6e-05	5.46e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CDH1—salivary gland cancer	3.58e-05	5.42e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PTEN—salivary gland cancer	3.57e-05	5.42e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—HRAS—salivary gland cancer	3.55e-05	5.38e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—PIK3CA—salivary gland cancer	3.55e-05	5.37e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PTEN—salivary gland cancer	3.52e-05	5.33e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—HRAS—salivary gland cancer	3.5e-05	5.31e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—PIK3CA—salivary gland cancer	3.46e-05	5.25e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—CREBBP—salivary gland cancer	3.45e-05	5.23e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—HRAS—salivary gland cancer	3.42e-05	5.18e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EP300—salivary gland cancer	3.41e-05	5.16e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—HRAS—salivary gland cancer	3.39e-05	5.14e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EP300—salivary gland cancer	3.36e-05	5.09e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—TP53—salivary gland cancer	3.35e-05	5.08e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—HRAS—salivary gland cancer	3.33e-05	5.05e-05	CbGpPWpGaD
Afatinib—LCK—Disease—CREBBP—salivary gland cancer	3.33e-05	5.04e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—HRAS—salivary gland cancer	3.28e-05	4.97e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAP2K2—salivary gland cancer	3.26e-05	4.93e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—PIK3CA—salivary gland cancer	3.24e-05	4.9e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—HRAS—salivary gland cancer	3.2e-05	4.86e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAP2K2—salivary gland cancer	3.14e-05	4.76e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PTEN—salivary gland cancer	3.13e-05	4.74e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—PIK3CA—salivary gland cancer	3.12e-05	4.73e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—CREBBP—salivary gland cancer	3.12e-05	4.72e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—PIK3CA—salivary gland cancer	3.11e-05	4.71e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—PIK3CA—salivary gland cancer	2.99e-05	4.54e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—HRAS—salivary gland cancer	2.99e-05	4.54e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EP300—salivary gland cancer	2.98e-05	4.52e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—HRAS—salivary gland cancer	2.89e-05	4.37e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—HRAS—salivary gland cancer	2.88e-05	4.36e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—PIK3CA—salivary gland cancer	2.82e-05	4.27e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—salivary gland cancer	2.77e-05	4.2e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CREBBP—salivary gland cancer	2.7e-05	4.09e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—salivary gland cancer	2.68e-05	4.06e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PTEN—salivary gland cancer	2.67e-05	4.05e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOTCH1—salivary gland cancer	2.67e-05	4.04e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—salivary gland cancer	2.61e-05	3.95e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTEN—salivary gland cancer	2.58e-05	3.92e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PTEN—salivary gland cancer	2.57e-05	3.9e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOTCH1—salivary gland cancer	2.57e-05	3.9e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—EP300—salivary gland cancer	2.55e-05	3.86e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PIK3CA—salivary gland cancer	2.52e-05	3.82e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PIK3CA—salivary gland cancer	2.48e-05	3.76e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTEN—salivary gland cancer	2.47e-05	3.74e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EP300—salivary gland cancer	2.46e-05	3.73e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EP300—salivary gland cancer	2.46e-05	3.72e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—salivary gland cancer	2.44e-05	3.7e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CREBBP—salivary gland cancer	2.42e-05	3.67e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—salivary gland cancer	2.4e-05	3.64e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTEN—salivary gland cancer	2.38e-05	3.6e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—EP300—salivary gland cancer	2.35e-05	3.57e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—salivary gland cancer	2.33e-05	3.53e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CREBBP—salivary gland cancer	2.33e-05	3.53e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—salivary gland cancer	2.3e-05	3.48e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EP300—salivary gland cancer	2.27e-05	3.44e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—PIK3CA—salivary gland cancer	2.21e-05	3.34e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CA—salivary gland cancer	2.06e-05	3.13e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—salivary gland cancer	2.04e-05	3.09e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTEN—salivary gland cancer	1.93e-05	2.92e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—salivary gland cancer	1.91e-05	2.89e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CA—salivary gland cancer	1.88e-05	2.86e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—EP300—salivary gland cancer	1.84e-05	2.79e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CA—salivary gland cancer	1.82e-05	2.76e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CA—salivary gland cancer	1.82e-05	2.75e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—salivary gland cancer	1.79e-05	2.71e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—salivary gland cancer	1.76e-05	2.67e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—salivary gland cancer	1.74e-05	2.64e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CA—salivary gland cancer	1.74e-05	2.64e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTEN—salivary gland cancer	1.73e-05	2.62e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—salivary gland cancer	1.72e-05	2.61e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—salivary gland cancer	1.69e-05	2.56e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—salivary gland cancer	1.68e-05	2.55e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CA—salivary gland cancer	1.68e-05	2.54e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTEN—salivary gland cancer	1.66e-05	2.52e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EP300—salivary gland cancer	1.65e-05	2.5e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—salivary gland cancer	1.61e-05	2.44e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EP300—salivary gland cancer	1.59e-05	2.41e-05	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—salivary gland cancer	1.55e-05	2.35e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CREBBP—salivary gland cancer	1.46e-05	2.21e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CA—salivary gland cancer	1.36e-05	2.06e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CA—salivary gland cancer	1.22e-05	1.85e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—salivary gland cancer	1.18e-05	1.79e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CA—salivary gland cancer	1.17e-05	1.78e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—salivary gland cancer	1.14e-05	1.72e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—salivary gland cancer	1.13e-05	1.71e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—salivary gland cancer	1.09e-05	1.65e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTEN—salivary gland cancer	1.04e-05	1.58e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—EP300—salivary gland cancer	9.94e-06	1.51e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CA—salivary gland cancer	7.36e-06	1.11e-05	CbGpPWpGaD
